The recruitment crisis is the industry's oldest unsolved problem

If clinical research has one chronic disease, it is patient recruitment. Trials cannot find, enroll, and keep enough participants, and they have struggled with it for decades. The numbers are stark, and because recruitment failure is the most common reason trials die, they are also a direct signal about which jobs the industry cannot afford to under-resource.

The numbers

The headline figures are grim and consistent across sources. Roughly 80 percent of trials fail to meet their initial enrollment target and timeline, by one systematic review, and enrollment delays can cost drug developers up to $8 million a day in lost revenue. A widely cited figure holds that about 86 percent of trials miss their original recruitment deadline. In oncology specifically, one analysis of over ten thousand recruiting trials found 60 percent enrolled fewer than five participants per site, and more than 20 percent enrolled none at all. Fewer than 4 percent of US adults ever participate in a clinical trial.

A foundational Tufts analysis, now dated to 2012 but still the benchmark of its kind, found that across some 16,000 sites, 48 percent under-enrolled, including the 11 percent that enrolled not a single patient. Only 47 percent of studies completed enrollment on schedule; the rest needed extensions, and one in six took more than twice as long as planned. Flag the year when you cite it, but the pattern has not fundamentally changed.

Why this is a labor story

Recruitment failure is not just an operational headache; it is the reason several jobs exist and a reason they should be better staffed. When roughly half of selected sites under-enroll, the functions that pick better sites and help them recruit, feasibility, site selection, and patient recruitment, are working directly on the industry's most expensive problem. The data is, in effect, a standing argument that these roles are undervalued relative to the money they save. A day of enrollment delay costs more than a feasibility analyst's salary for months.

For CRAs and coordinators, the recruitment crisis shows up as pressure: enrollment targets that follow you, sites that cannot deliver, and the constant tension between speed and quality. Understanding that the whole industry struggles with this, that your under-enrolling site is the norm and not your failure, is worth something on its own.

The opportunity inside the crisis

A chronic, expensive, unsolved problem is also a durable source of demand for the people who can address it. The skills that improve recruitment, realistic feasibility assessment, honest site selection, protocol simplification, patient-facing coordination, sit on the industry's most persistent pain point. In a field worried about automation and offshoring, the recruitment problem is stubbornly human, and the roles that work on it are correspondingly durable.

What the statistics cannot tell you

The enrollment data tells you trials fail to recruit. It cannot tell you what that pressure does to the people carrying it, whether the feasibility and recruitment roles are actually paid for the value they create, or how the workload lands on coordinators when a site cannot fill. Those are the lived realities behind the statistic, and they only exist with the workers who live them. If recruitment pressure shapes your job, add your datapoint, and put the human side on the industry's oldest number.